Nathan T Connell1, Tracey Cheves2, Joseph D Sweeney2. 1. Hematology Division, Brigham and Women's Hospital, Boston, Massachusetts. 2. Department of Pathology & Laboratory Medicine, Rhode Island Hospital, Providence, Rhode Island.
Abstract
BACKGROUND: Thrombotic thrombocytopenic purpura (TTP) due to deficiency of the von Willebrand-cleaving protease ADAMTS13 is a hematologic emergency that requires prompt initiation of therapeutic plasma exchange (TPE). Long turnaround times (TATs) have precluded the use of pre-TPE measurement of ADAMTS13 activity for the initial diagnosis in most institutions. STUDY DESIGN AND METHODS: An in-house rapid TAT (r-TAT) assay for ADAMTS13 activity was implemented after 18 months of validation. In a quasi-experimental design using interrupted time series analysis, patterns of plasma utilization in patients with suspected TTP were assessed after implementation of this assay for ADAMTS13 activity and compared to utilization patterns for patients who received plasma exchange before r-TAT assay implementation designated the standard TAT period. RESULTS: In the 18 months after implementation of the r-TAT ADAMTS13 assay, there was a significant reduction in plasma utilization per patient suspected of having TTP (mean, 144.5 units vs. 63.3 units of plasma per patients suspected of having TTP; p = 0.002). The mean number of exchanges per patient and mean number of exchanges after achieving a platelet count of at least 150 × 10(9) /L were lower in the r-TAT cohort (p < 0.001 for both). There was no significant difference in 30-day mortality. CONCLUSIONS: Implementation of a rapid turnaround assay for ADAMTS13 resulted in a significant reduction in plasma utilization for patients with suspected TTP, without an increase in mortality. This study demonstrates that these data, provided in a timely fashion, can avoid unnecessary plasma exchange in patients who do not have TTP.
BACKGROUND:Thrombotic thrombocytopenic purpura (TTP) due to deficiency of the von Willebrand-cleaving protease ADAMTS13 is a hematologic emergency that requires prompt initiation of therapeutic plasma exchange (TPE). Long turnaround times (TATs) have precluded the use of pre-TPE measurement of ADAMTS13 activity for the initial diagnosis in most institutions. STUDY DESIGN AND METHODS: An in-house rapid TAT (r-TAT) assay for ADAMTS13 activity was implemented after 18 months of validation. In a quasi-experimental design using interrupted time series analysis, patterns of plasma utilization in patients with suspected TTP were assessed after implementation of this assay for ADAMTS13 activity and compared to utilization patterns for patients who received plasma exchange before r-TAT assay implementation designated the standard TAT period. RESULTS: In the 18 months after implementation of the r-TAT ADAMTS13 assay, there was a significant reduction in plasma utilization per patient suspected of having TTP (mean, 144.5 units vs. 63.3 units of plasma per patients suspected of having TTP; p = 0.002). The mean number of exchanges per patient and mean number of exchanges after achieving a platelet count of at least 150 × 10(9) /L were lower in the r-TAT cohort (p < 0.001 for both). There was no significant difference in 30-day mortality. CONCLUSIONS: Implementation of a rapid turnaround assay for ADAMTS13 resulted in a significant reduction in plasma utilization for patients with suspected TTP, without an increase in mortality. This study demonstrates that these data, provided in a timely fashion, can avoid unnecessary plasma exchange in patients who do not have TTP.
Authors: Chong H Kim; Sierra C Simmons; Lance A Williams; Elizabeth M Staley; X Long Zheng; Huy P Pham Journal: Transfusion Date: 2017-06-23 Impact factor: 3.157
Authors: T Sakari Jokiranta; Ondrej Viklicky; Saleh Al Shorafa; Rosanna Coppo; Christoph Gasteyger; Manuel Macia; Tatiana Pankratenko; Mohan Shenoy; Oğuz Soylemezoglu; Michel Tsimaratos; Jack Wetzels; Hermann Haller Journal: BMC Nephrol Date: 2017-10-28 Impact factor: 2.388
Authors: Nicolas Beranger; Sandrine Benghezal; Bérangère S Joly; Sophie Capdenat; Adeline Delton; Alain Stepanian; Paul Coppo; Agnès Veyradier Journal: Res Pract Thromb Haemost Date: 2020-12-15
Authors: Michael Ryan; Bonnie M K Donato; William Irish; Christoph Gasteyger; Gilbert L'Italien; Jeffrey Laurence Journal: Pharmacoeconomics Date: 2020-03 Impact factor: 4.981